Open AccessBurden of illness and outcomes in second-line large B-cell lymphoma treatment: real-world analysis of Medicare beneficiaries
Author(s) -
Karl M. Kilgore,
Iman Mohammadi,
Anna Wong,
Julia Thornton Snider,
Paul Cheng,
Amy Schroeder,
Ayushi Patel
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0607
Subject(s) - medicine , population , regimen , chemotherapy regimen , retrospective cohort study , lymphoma , cohort , health care , b cell lymphoma , oncology , chemotherapy , environmental health , economics , economic growth
Aims: To characterize elderly large B-cell lymphoma patients who progress to second-line treatment to identify potential unmet treatment needs. Patients & methods: Retrospective USA cohort study, patients receiving second-line autologous stem cell transplant (SCT) preparative regimen (‘ASCT-intended’) versus those who did not; stratified further into those who received a stem cell transplant and those who did not. Primary outcomes were: healthcare resource utilization, costs and adverse events. Results: 1045 patients (22.0%) were included in the ASCT-intended group, 23.3% of whom received SCT (5.1% of entire second-line population). Non-SCT patients were older and had more comorbidities and generally higher rates of healthcare resource utilization and costs. Conclusion: Elderly second-line large B-cell lymphoma patients incurred substantial costs and a minority received potentially curative SCT, suggesting significant unmet need.